Apollo scores big with Millipore

By Staff Writers
Tuesday, 21 August, 2007


Sydney biotech Apollo Life Sciences has signed a supply agreement with US giant Millipore to supply human Leukaemia Inhibitory Factor (hLIF) for resale in worldwide markets. LIF is a patented protein that plays a role in the growth and development of cells. Millipore is the exclusive worldwide supplier of human LIF, a cytokine that can be used to prevent stem cells from differentiating into more specialised cell types.

Apollo's human cell-expressed LIF may allow researchers to maintain stem cells in an undifferentiated state prior to transformation into specialised cells such as heart muscle cells.

Apollo will use its proprietary human cell-expressed (hcx) protein technology to produce human LIF for sale by Millipore under Apollo's hcx trademark. The company's first supply of hcx LIF to Millipore is scheduled for later this month.

Apollo's hcx LIF mimics endogenously-produced human LIF as it contains the same types of sugar modifications, the company said in a statement.

Such human-specific sugar modifications are not found on LIF proteins expressed from rodent or bacterial cells, it said.

Related Articles

Bright nights may increase risk of death, Alzheimer's

Avoiding night light and seeking daylight may lead to reduction in disease burden, especially...

COVID-19 infection increases risk of heart attack and stroke

COVID-19 infection may increase the risk of heart attack, stroke and death from any cause for up...

A bout of COVID could protect you from a severe case of flu

Recovery from COVID appears to have a protective effect against the worst effects of the flu,...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd